Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Identification of Calr Mutations in Individuals of the Background Population Reveals Undiagnosed Myeloproliferative Neoplasms and Surprisingly Stable Low Levels of Calr Mutant Allele Burden in Individuals Not Developing Myeloproliferative Neoplasm during 10-14 Year Follow-up

Lasse Kjær, Morten Kranker Larsen, Vibe Skov, Trine Alma Knudsen, Sabrina Cordua Bech, Jordan A. Snyder, Johanne Gudmand-Høyer, Morten Andersen, Johnny T. Ottesen, Thomas Stiehl, Christina Ellervik, Hans C. Hasselbalch

Blood (2024) 144 (Supplement 1): 1806.

https://doi.org/10.1182/blood-2024-210127

Published: 2024

Journal Articles

Statins Enhance the Efficacy of Pegylated Interferon-alpha2 in Patients with Ph-Negative Chronic Myeloproliferative Neoplasms. Results from a Danish Single-Institution Cohort Study

Isabella Diana Hansen, Morten Kranker Larsen, Vibe Skov, Lasse Kjær, Christina Ellervik, Anders Lindholm Sørensen, Trine Alma Knudsen, Sarah Friis Christensen, Sabrina Cordua, Christina Schjellerup Eickhardt-Dalbøge, Troels Wienecke, Marie Hvelplund Kristiansen, Hans C. Hasselbalch

Blood (2024) 144 (Supplement 1): 3184.

https://doi.org/10.1182/blood-2024-203051

Published: 2024

Journal Articles

Risk of Fractures in Individuals with Hemochromatosis HFE C282Y Homozygosity and in Individuals with Low or High Levels of Plasma Iron, Transferrin Saturation, or Ferritin: A Prospective Study of 142,146 General Population Individuals

Jens Helby, Marie Warny, Stig Egil Bojesen, Boerge Groenne Nordestgaard, Jesper Petersen, Christina Ellervik, Andreas Glenthoej

Blood (2024) 144 (Supplement 1): 1087.

https://doi.org/10.1182/blood-2024-202616

Published: 2024

Journal Articles

Iron, hemochromatosis genotypes, and risk of infections: a cohort study of 142 188 general population individuals

Mathis Mottelson, Andreas Glenthøj, Børge Grønne Nordestgaard, Christina Ellervik, Jesper Petersen, Stig Egil Bojesen, Jens Helby

Blood (2024) 144 (7): 693–707.

https://doi.org/10.1182/blood.2023022235

Published: 2024

Includes: Supplemental data

Journal Articles

Final Analysis of the Daliah Trial: A Randomized Phase III Trial of Interferon-α Versus Hydroxyurea in Patients with MPN

Blood (2023) 142 (Supplement 1): 746.

https://doi.org/10.1182/blood-2023-173127

Published: 2023

Journal Articles

Absolute and Relative Risks of Hematologic Disease and Cause-Specific Death in Individuals with Incidentally Discovered Thrombocytopenia: A Prospective Study of Two Independent General Population Cohorts Including 486,782 Individuals from the United Kingdom and Denmark

Anne Rudbeck Juhl, Andreas Glenthoej, Boerge Groenne Nordestgaard, Jesper Petersen, Morten Dahl, Christina Ellervik, Stig Egil Bojesen, Jens Helby

Blood (2023) 142 (Supplement 1): 395.

https://doi.org/10.1182/blood-2023-173792

Published: 2023

Journal Articles

Quality of Life and Symptom Burden of Patients with MPN during Treatment with Hydroxyurea or Pegylated Interferon-alpha2: Results from a Randomized Controlled Trial

Blood (2022) 140 (Supplement 1): 1794–1796.

https://doi.org/10.1182/blood-2022-156445

Published: 2022

Journal Articles

Prevalence of the JAK2V617F Mutation in Patients with Ischemic Stroke

Marie H. Kristiansen, Vibe Skov, Lasse Kjær, Morten Kranker Kranker Larsen, Christina Ellervik, Hans Carl Hasselbalch, Troels Wienecke

Blood (2022) 140 (Supplement 1): 3949–3950.

https://doi.org/10.1182/blood-2022-156629

Published: 2022

Journal Articles

Neutrophil-to-Lymphocyte Ratio As a Predictor of All-Cause Mortality in the General Population and Patients with Myeloproliferative Neoplasms

Morten Kranker Kranker Larsen, Vibe Skov, Lasse Kjær, Henrik E. Poulsen, Christina S. Eickhardt-Dalbøge, Trine A. Knudsen, Sarah F. Christensen, Anders L. Sørensen, Marie H. Kristiansen, Troels Wienecke, Rasmus K. Pedersen, Morten Andersen, Johnny T. Ottesen, Thomas Stiehl, Christina Ellervik, Hans Carl Hasselbalch

Blood (2022) 140 (Supplement 1): 6842–6843.

https://doi.org/10.1182/blood-2022-165252

Published: 2022

Journal Articles

Combination Therapy with Ruxolitinib and Interferon in Newly Diagnosed Patients with Polycythemia Vera

Anders Lindholm Lindholm Sørensen, Vibe Skov, Lasse Kjær, Christina Schjellerup Schjellerup Eickhardt-Dalbøge, Morten Kranker Larsen, Claus Nielsen, Carsten Thomsen, Lise Mette Rahbek Gjerdrum, Trine Alma Knudsen, Christina Ellervik, Ulrik Malthe Overgaard, Christen Lykkegaard Andersen, Mads Emil Bjørn, Hans Carl Hasselbalch

Blood (2022) 140 (Supplement 1): 6806–6807.

https://doi.org/10.1182/blood-2022-157397

Published: 2022

Journal Articles

Interferon-alpha2 Favorably Impacts Deregulated Atherosclerosis Genes in Polycythemia Vera and Related Neoplasms

Vibe Skov, Mads Thomassen, Lasse Kjær, Morten Kranker Larsen, Christina Ellervik, Trine Alma Knudsen, Torben A. Kruse, Hans Carl Hasselbalch

Blood (2022) 140 (Supplement 1): 9604–9605.

https://doi.org/10.1182/blood-2022-157906

Published: 2022

Journal Articles

Patients with Essential Thrombocythemia Have a Gut Microbiota That Differs from Healthy Controls

Christina Schjellerup Schjellerup Eickhardt-Dalbøge, Anna Cäcilia Ingham, Lee O'Brien Andersen, Henrik V Nielsen, Kurt Fuursted, Christen Rune Stensvold, Morten Kranker Larsen, Lasse Kjær, Sarah F. Christensen, Trine A. Knudsen, Vibe Skov, Christina Ellervik, Lars Rønn Olsen, Hans Carl Hasselbalch, Xiaohui Chen Nielsen, Jens Jørgen Elmer Christensen

Blood (2022) 140 (Supplement 1): 12178–12179.

https://doi.org/10.1182/blood-2022-166031

Published: 2022

Journal Articles

The Gut Microbiota in Patients with Polycythemia Vera: Novel Vs. Conventional Treatments

Christina Schjellerup Schjellerup Eickhardt-Dalbøge, Anna Cäcilia Ingham, Lee O'Brien Andersen, Henrik V Nielsen, Kurt Fuursted, Morten Kranker Larsen, Lasse Kjær, Sarah Friis Christensen, Trine Alma Knudsen, Vibe Skov, Christina Ellervik, Hans C. Hasselbalch, Jens Jørgen Elmer Christensen, Xiaohui Chen Nielsen

Blood (2021) 138 (Supplement 1): 1501.

https://doi.org/10.1182/blood-2021-148350

Published: 2021

Journal Articles

The Impact of Somatic Mutations upon the Response to Combination Therapy with Ruxolitinib and Interferon in MPN Patients

Vibe Skov, Anders Lindholm Sørensen, Trine Alma Knudsen, Mads Emil Bjørn, Christina Ellervik, Morten Kranker Larsen, Christina Schjellerup Schjellerup Eickhardt-Dalbøge, Sarah Friis Christensen, Mads Thomassen, Torben A Kruse, Hans C. Hasselbalch

Blood (2021) 138 (Supplement 1): 3589.

https://doi.org/10.1182/blood-2021-152154

Published: 2021

Journal Articles

Superiority of IFN Versus HU Using a Novel Biomarker-Based Tool for Assessment of Disease Burden in MPNs

Vibe Skov, PhD, Marc JB Dam, Rasmus K Pedersen, Morten Andersen, PhD, Trine Alma Knudsen, MD, Zamra Sajid, Lasse Kjær, PhD, Christina Ellervik, MD PhD, Hans Hasselbalch, MD, Johnny T Ottesen, PhD

Blood (2019) 134 (Supplement_1): 2972.

https://doi.org/10.1182/blood-2019-126819

Published: 2019

Journal Articles

Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response

Blood (2019) 134 (Supplement_1): 4202.

https://doi.org/10.1182/blood-2019-126164

Published: 2019

Journal Articles

Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population

Sabrina Cordua, Lasse Kjaer, Vibe Skov, Niels Pallisgaard, Hans C. Hasselbalch, Christina Ellervik

Blood (2019) 134 (5): 469–479.

https://doi.org/10.1182/blood.2019001113

Published: 2019

Includes: Supplemental data

Journal Articles

The Association between Circulating Inflammatory Markers and Metabolic Syndrome: A General Population Study

Kasper Mønsted Pedersen, MD, Sabrina Cordua, MD, Hans Carl Hasselbalch, Professor, dr.MD, Christina Ellervik, Associate Professor, MD PhD

Blood (2018) 132 (Supplement 1): 4305.

https://doi.org/10.1182/blood-2018-99-120356

Published: 2018

Journal Articles

Genetic Evidence for Involvement of Human Endogenous Retrovirus Herv-Fc1 in the Pathogenesis of MPNs

Vibe Skov, PhD, Katrine LM Schmidt, Kasper Mønsted Pedersen, MD, Bettina Hansen, Tobias Wirenfeldt Klausen, M.S., Torben A Kruse, Mads Thomassen, PhD, Lasse Kjær, PhD, Christina Ellervik, Associate Professor, MD PhD, Morten Holmstrøm, MD, Bjørn Nexø, Hans Carl Hasselbalch, Professor, dr.MD, Magdalena J Laska

Blood (2018) 132 (Supplement 1): 5488.

https://doi.org/10.1182/blood-2018-99-118080

Published: 2018

Journal Articles

Cigarette Smoking, Complete Blood Count, and Myeloproliferative Neoplasms — a Meta-Analysis

Nimesh A Jayasuriya, Christina Ellervik, Associate Professor, MD PhD, Hans Carl Hasselbalch, MD Professor, DMSc, Anders Sørensen

Blood (2017) 130 (Supplement 1): 4199.

https://doi.org/10.1182/blood.V130.Suppl_1.4199.4199

Published: 2017

NARROW

Identification of Calr Mutations in Individuals of the Background Population Reveals Undiagnosed Myeloproliferative Neoplasms and Surprisingly Stable Low Levels of Calr Mutant Allele Burden in Individuals Not Developing Myeloproliferative Neoplasm during 10-14 Year Follow-up

Statins Enhance the Efficacy of Pegylated Interferon-alpha2 in Patients with Ph-Negative Chronic Myeloproliferative Neoplasms. Results from a Danish Single-Institution Cohort Study

Risk of Fractures in Individuals with Hemochromatosis HFE C282Y Homozygosity and in Individuals with Low or High Levels of Plasma Iron, Transferrin Saturation, or Ferritin: A Prospective Study of 142,146 General Population Individuals

Iron, hemochromatosis genotypes, and risk of infections: a cohort study of 142 188 general population individuals

Final Analysis of the Daliah Trial: A Randomized Phase III Trial of Interferon-α Versus Hydroxyurea in Patients with MPN

Absolute and Relative Risks of Hematologic Disease and Cause-Specific Death in Individuals with Incidentally Discovered Thrombocytopenia: A Prospective Study of Two Independent General Population Cohorts Including 486,782 Individuals from the United Kingdom and Denmark

Quality of Life and Symptom Burden of Patients with MPN during Treatment with Hydroxyurea or Pegylated Interferon-alpha2: Results from a Randomized Controlled Trial

Prevalence of the JAK2V617F Mutation in Patients with Ischemic Stroke

Neutrophil-to-Lymphocyte Ratio As a Predictor of All-Cause Mortality in the General Population and Patients with Myeloproliferative Neoplasms

Combination Therapy with Ruxolitinib and Interferon in Newly Diagnosed Patients with Polycythemia Vera

Interferon-alpha2 Favorably Impacts Deregulated Atherosclerosis Genes in Polycythemia Vera and Related Neoplasms

Patients with Essential Thrombocythemia Have a Gut Microbiota That Differs from Healthy Controls

The Gut Microbiota in Patients with Polycythemia Vera: Novel Vs. Conventional Treatments

The Impact of Somatic Mutations upon the Response to Combination Therapy with Ruxolitinib and Interferon in MPN Patients

Superiority of IFN Versus HU Using a Novel Biomarker-Based Tool for Assessment of Disease Burden in MPNs

Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response

Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population

The Association between Circulating Inflammatory Markers and Metabolic Syndrome: A General Population Study

Genetic Evidence for Involvement of Human Endogenous Retrovirus Herv-Fc1 in the Pathogenesis of MPNs

Cigarette Smoking, Complete Blood Count, and Myeloproliferative Neoplasms — a Meta-Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only